Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03994601 · ClinicalTrials.gov registry record · Phase 1
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 219
- Enrollment target
NCT03994601 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 219 participants.
The verdict
NCT03994601, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 219 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether BMS-986288 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of select advanced solid tumors.
Interventions
- DRUG Nivolumab
- DRUG Regorafenib
- DRUG BMS-986288
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2019-09-06 |
| Est. Completion | 2024-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03994601
The ClinicalTrials.gov registry entry for NCT03994601 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 219 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT03994601 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03994601 about?
NCT03994601 is a clinical study titled "An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers". The purpose of this study is to determine whether BMS-986288 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of select advanced solid tumors.
What is the current status of trial NCT03994601?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 219 participants. The study started on 2019-09-06. Estimated completion is 2024-08-31.
What interventions are being tested in trial NCT03994601?
The interventions under investigation include: Nivolumab (DRUG), Regorafenib (DRUG), BMS-986288 (DRUG).
Who is sponsoring clinical trial NCT03994601?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.